Joel Greshock
Overview
Explore the profile of Joel Greshock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
4176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Demirdjian L, Triantos S, Standish K, Thomas S, Xia Q, Zhang J, et al.
Cancer Med
. 2025 Feb;
14(4):e70546.
PMID: 40007233
Background: Somatic FGFR gene alterations (FGFRalt) may act as oncogenic drivers across several cancers. The prognostic impact of FGFRalt in solid tumors is not fully understood. We assessed the prognostic...
2.
Feng F, Smith M, Saad F, Mobadersany P, Tian S, Yip S, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400653.
PMID: 39889245
Purpose: The SPARTAN trial demonstrated that the addition of apalutamide to androgen deprivation therapy improves outcomes among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). We applied a previously reported digital...
3.
Merola D, Campbell U, Lenis D, Schneeweiss S, Wang S, Madsen A, et al.
JAMA Netw Open
. 2024 Sep;
7(9):e2436535.
PMID: 39348118
Importance: The conditions required for health record data sources to accurately assess treatment effectiveness remain unclear. Emulation of randomized clinical trials (RCTs) with health record data and subsequent calibration of...
4.
Juan Ramon A, Parmar C, Carrasco-Zevallos O, Csiszer C, Yip S, Raciti P, et al.
Nat Commun
. 2024 Jun;
15(1):4690.
PMID: 38824132
Accurate identification of genetic alterations in tumors, such as Fibroblast Growth Factor Receptor, is crucial for treating with targeted therapies; however, molecular testing can delay patient care due to the...
5.
Abelin J, Harjanto D, Malloy M, Suri P, Colson T, Goulding S, et al.
Immunity
. 2021 Feb;
54(2):388.
PMID: 33567264
No abstract available.
6.
Ott P, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, et al.
Cell
. 2020 Oct;
183(2):347-362.e24.
PMID: 33064988
Neoantigens arise from mutations in cancer cells and are important targets of T cell-mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based...
7.
Greshock J, Lewi M, Hartog B, Tendler C
Trends Cancer
. 2020 Sep;
6(11):907-909.
PMID: 32972882
Resourcing real-world evidence (RWE) is becoming an increasingly important asset in developing novel therapies for cancer. In this article, an overview of the benefits and challenges of using these data...
8.
Abelin J, Harjanto D, Malloy M, Suri P, Colson T, Goulding S, et al.
Immunity
. 2019 Sep;
51(4):766-779.e17.
PMID: 31495665
Increasing evidence indicates CD4 T cells can recognize cancer-specific antigens and control tumor growth. However, it remains difficult to predict the antigens that will be presented by human leukocyte antigen...
9.
Horn T, Ferretti S, Ebel N, Tam A, Ho S, Harbinski F, et al.
Cancer Res
. 2016 Sep;
76(23):6950-6963.
PMID: 27659046
Like classical chemotherapy regimens used to treat cancer, targeted therapies will also rely upon polypharmacology, but tools are still lacking to predict which combinations of molecularly targeted drugs may be...
10.
Longo T, McGinley K, Freedman J, Etienne W, Wu Y, Sibley A, et al.
Eur Urol
. 2016 Aug;
70(5):714-717.
PMID: 27520487
Patient Summary: In this report we found known, as well as previously unreported, genetic mutations in the tumors of patients with high-risk bladder cancer. These mutations, if validated, may serve...